Nubeqa (darolutamide) is approved for use in both non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). I am neither. Scans showed only showed tumor activity in vas deferens stump, nowhere else. Lupron has worked for me in the past, so can’t we assume ADT will still work? That means I am non -metastatic castration sensitive which is not in either category it is approved for? The Embark study and others did not focus on non-metastatic castration sensitive. Then again Orgovyx is approved for the same two classifications. I can’t help wondering if either one would be ok, rather than the twofer.